NPPB and Stroke: Compared with placebo, SGLT2i following MI had no beneficial impact on cardiovascular deaths (OR: 1.04; 95% CI: 0.83-1.30; p=0.76; <i>I</i> <sup>2</sup>=0%), all-cause mortality (OR: 1.00; 95% CI: 0.82-1.21; p=0.98; <i>I</i> <sup>2</sup>=0%), stroke (OR: 0.58; 95% CI: 0.26-1.27; p=0.17), all-cause hospitalization (OR: 1.13; 95% CI: 0.97-1.32; p=0.11; <i>I</i> <sup>2</sup>=0%) and percentage change in NT-proBNP (MD: 1.18%; 95% CI: -9.78 to 12.14; p=0.83; <i>I</i> <sup>2</sup>=52%).